Table 1 (abstract P226). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | All patients | MTX-tolerant | MTX-intolerant | p-value | MTX-intolerant girls | MTX-intolerant boys | p-value |
|---|---|---|---|---|---|---|---|
Number of patients | 118 | 46 | 72 | - | 50 (62.5%) | 22 (57.9%) | - |
Girls:boys, n, (% females) | 80;38 (68%) | 30;16(65%) | 50;22 (69%) | 0.78 | Â | Â | - |
Age at enrollment, years | 13.4(11.3-15.2) | 13.8(11.5-15.4) | 13.3(11.1-14.6) | 0.34 | 12.8(11.1-15.3) | 13.7(12.2-14.3) | 0.76 |
MTXo:MTXsc, n | 44:74 | 21:25 | 23:49 | 0.19 | 15:35 | 8:14 | 0.80 |
MTX-dose (mg/m2 pr. week) | 9.75(9-10.98) | 10.1(9.4-10.9) | 9.6 (8.6-11) | 0.12 | 9.7(8.4-11.1) | 9.6(9.2-10.6) | 1.00 |
MTX treatment duration, days | 334 (141.2-756.8) | 261.5(141.2-611.8) | 335 (142.5-778.5) | 0.40 | 399.5(146.8-938.5) | 284 (130.8-602.8) | 0.41 |